广生堂子公司广生中霖参与新发突发与重大传染病防控国家科技重大专项

Group 1 - The core point of the article is that Guangshengtang's subsidiary, Fujian Guangsheng Zhonglin Biotechnology Co., Ltd., has received a project completion notice for a national major science and technology project focused on the clinical cure of chronic hepatitis B [1] - Guangsheng Zhonglin will participate in the research of the project, specifically in topics one and three, and will be responsible for the research work [1] - The innovative drugs GST-HG131 and GST-HG141, along with combination therapies, will be used as research medications for the project [1]